期刊文献+

Effect of S-1 combined with oxaliplatin on serum tumor markers,matrix metalloproteinase and immune function in elderly patients with gastric cancer

在线阅读 下载PDF
导出
摘要 Objective: To investigate the effect of Compound Tegafur and Oteracil Potassium Sustained Capsules (S-1) combined with oxaliplatin chemotherapy on serum tumor marker matrix metalloproteinase and immune function in elderly patients with gastric cancer. Methods:According to the random data table, 80 cases of elderly patients with gastric cancer were divided into control group and observation group (n=40), patients in the control group were treated with oxaliplatin combined with Capecitabine Tablets, and the observation group patients were treated with S-1 combined with oxaliplatin, all treated for 6 cycles, before and after treatment, levels of serum tumor markers, matrix metalloproteinase and immune function were compared between the two groups. Results: Before treatment, there was no significant difference in the levels of CEA, CA125, CA19-9, MMP-2, MMP-9, CD3+, CD4+, CD8+and CD4+/CD8+between the two groups;After treatment, the levels of CEA, CA125, CA19-9, MMP-2, MMP-9 and CD8+in the two groups were significantly lower than those in the same group before treatment, and the levels of the observation group[(7.79±2.78) ng/mL, (22.56±7.31) U/mL, (13.48±3.05) U/mL, (57.84±8.93) ng/mL, (199.14±67.39) ng/mL and (26.21±4.18)%] were significantly lower than those in the control group;Compared with the group before treatment, the levels of CD3+, CD4+and CD4+/CD8+in the two groups were significantly increased, and the observation group [(66.89±5.84)%, (41.63±5.24)% and (1.37±0.29)] was significantly higher than the control group. Conclusion: S-1 combined with oxaliplatin chemotherapy can effectively reduce serum tumor markers and matrix metalloproteinase levels, improve immune function, has an important clinical value.
出处 《Journal of Hainan Medical University》 2017年第19期133-136,共4页 海南医学院学报(英文版)
作者简介 Corresponding author:Yong-Feng Shan,Department of Oncology,the Fifth People's Hospital of Wuxi,Jiangsu,Wuxi 214000,China.E-mail:shanyongfeng56@163.com.
  • 相关文献

参考文献2

二级参考文献32

  • 1陈浮,朱海杭,王璐.卡培他滨联合奥沙利铂术前新辅助化疗治疗中晚期胃癌的疗效分析[J].实用癌症杂志,2014,29(1):53-55. 被引量:28
  • 2张爱知,马伴吟.实用药物手册[M].6版.上海:上海科学技术出版社,2011.
  • 3Liu Y, Gu X, Lin Q, et aL Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta- analysis [J]. Int J Clin Exp Med, 2015, 8(8) :12765-12773.
  • 4Chimparlee N, Chuaypen N, Khlaiphuengsin A, et al. Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma [J]. Asian Pac J Cancer Prev, 2015, 16(16) : 7211- A7217.
  • 5Qiu Y, Hu Y, Zhang ZY, et al. Genetic association of os- teopontin (OPN) and its receptor CD44 genes with susceptibili- ty to Chinese gastric cancer patients [J]. J Cancer Res Clin On col, 2014, 140(12) :2143-2156.
  • 6Takaya S, Saito H, Ikeguchi M. Upregulation of Immune Check- point Molecules, PD-1 and LAG-3, on CD4q- and CDSq- T Cells after Gastric Cancer Surgery [J]. Yonago Acta Med, 2015, 58(1) :39-44.
  • 7Kouo T, Huang L, Pucsek AB, et al. Galectin-3 Shapes Antitu- mot Immune Responses by Suppressing CD8 q- T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells [J]. Cancer Immunol Res, 2015, 3(4):412-423.
  • 8Giakoustidis A, Giakoustidis D, Mudan S, et al. Molecular sig- nalling in hepatocellular carcinoma: Role of and crosstalk a- mong WNT/s-catenin, Sonic Hedgehog, Notch and DickkopPl [J]. Can J Gastroenterol Hepatol, 2015, 29(4) : 209-217.
  • 9Zhuang GF,Tan Y,Zeng JT,e1 aI. Expression o{ serum Dickko- pf-1 in gastric cancer patients [J]. Asian Pac J Trop Med, 2015, 8(10) :870-872.
  • 10Li Y, Zhou Y,Zheng J, et al. Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells [J]. Int J Clin Exp Pathol, 2015, 8(2) : 1731-1736.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部